Claudia Vasconcelos/LinkedIn
Apr 23, 2025, 16:07
Claudia Vasconcelos: DESTINY-Breast09 results could be practice-changing for patients with HER2+ MBC
Claudia Vasconcelos, Sr. Medical Director, Global Head, Breast and Gyn TA at Parexel, shared a post on LinkedIn:
“Sharing the positive topline results from DESTINY-Breast09!
Trastuzumab deruxtecan (T-DXd) in combination with pertuzumab demonstrated highly statistically significant and clinically meaningful improvement in PFS compared to taxane, trastuzumab and pertuzumab (THP) as 1st-line treatment for patients with HER2-positive metastatic breast cancer.
A protential practice-changing study for HER2+ MBC!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 14, 2025, 14:32
May 14, 2025, 13:48
May 14, 2025, 13:16
May 14, 2025, 13:14
May 14, 2025, 13:10
May 14, 2025, 12:52